Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Angptl3(angiopoietin-like 3)].

Tetsuya Shimizugawa1, Yosuke Ando, Mitsuru Ono

  • 1Pharmacology and Molecular Biology Research Laboratories, Sankyo Co., Ltd.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 23, 2004
PubMed
Summary

Angiopoietin-like 3 (Angptl3) deficiency lowers blood lipids by enhancing very low-density lipoprotein (VLDL) clearance. Repressing ANGPTL3 may reduce lipid levels and protect against atherosclerosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and clinical characteristics of zolbetuximab-induced nausea and vomiting in CLDN18.2-positive unresectable advanced or recurrent gastric cancer: a retrospective study.

Journal of pharmaceutical health care and sciences·2026
Same author

Association Between Anticholinergic Drug Use and Febrile Neutropenia Induced by Anticancer Chemotherapy: Analysis of the Japanese Adverse Drug Event Report Database.

In vivo (Athens, Greece)·2025
Same author

Comparison of standard and biweekly trifluridine/tipiracil plus bevacizumab regimens in advanced or recurrent colorectal cancer: a retrospective study.

Japanese journal of clinical oncology·2025
Same author

Impact of cancer type differences on chemotherapy-induced nausea and vomiting (CINV) incidence in oxaliplatin-based regimens for gastric and colorectal cancer: a retrospective study.

International journal of clinical oncology·2025
Same author

Impact of renal function on non-hematologic toxicities in mCRC patients treated with TAS-102: a post-hoc analysis of the JASCC-CINV2001 study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same author

Solvation-Layering-Assisted Formation of Highly Concentrated Colloidal Sub-10-nm-Diameter Layered Double Hydroxide Nanoparticles Using Acetylacetone.

Langmuir : the ACS journal of surfaces and colloids·2025

Area of Science:

  • Biochemistry
  • Genetics
  • Cardiovascular Science

Background:

  • Angiopoietin-like 3 (Angptl3) plays a role in lipid metabolism.
  • Dysregulation of Angptl3 is implicated in hypertriglyceridemia and atherosclerosis.

Purpose of the Study:

  • To investigate the role of Angptl3 in very low-density lipoprotein (VLDL) triglyceride clearance.
  • To explore the regulatory mechanisms of Angptl3 expression by Liver X receptor (LXR) ligands.
  • To assess the therapeutic potential of ANGPTL3 repression in atherosclerosis.

Main Methods:

  • Studied Angptl3-deficient mice and wild-type mice.
  • Utilized in vitro assays with recombinant human ANGPTL3 protein to assess lipoprotein lipase (LPL) activity.
  • Administered LXR ligands to mice to examine effects on Angptl3 gene promoter activity and plasma lipid levels.
  • Evaluated Angptl3-deficiency in apoE-deficient mice to assess atherosclerosis development.

Main Results:

  • Angptl3 deficiency led to significantly lower plasma lipid levels and enhanced VLDL clearance in mice.
  • Recombinant ANGPTL3 protein inhibited LPL activity in vitro, indicating Angptl3's role in VLDL triglyceride clearance.
  • LXR ligand treatment increased Angptl3 gene promoter activity, but did not elevate plasma triglycerides in Angptl3-deficient mice, suggesting Angptl3 overproduction drives LXR-induced hypertriglyceridemia.
  • Angptl3 deficiency reduced plasma lipid levels and aortic atherosclerotic lesions in apoE-deficient mice.

Conclusions:

  • Angptl3 is a key regulator of plasma lipid levels, primarily through its influence on VLDL triglyceride clearance via LPL inhibition.
  • Liver X receptor (LXR) activation upregulates Angptl3, contributing to hypertriglyceridemia.
  • Targeting ANGPTL3 represents a promising strategy for managing hyperlipidemia and preventing atherosclerosis.

Related Experiment Videos